Unveiling the signature of transposable elements-derived transcripts – the transposcriptome – as a biomarker in human acute myeloid leukemia

Projektinformationen

LEUKEMIC-TEs

ID Finanzhilfevereinbarung: 747203

DOI 10.3030/747203

Abgeschlossenes Projekt

EK-Unterschriftsdatum 20 Februar 2017

Startdatum 1 April 2017

Enddatum 31 März 2019

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 175 419,60

EU-Beitrag € 175 419,60

Koordiniert durch

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Switzerland

Ziel

Acute myeloid leukemia (AML) is the most common of the acute leukemias among adults. Relapsed AML patients are frequent but difficult to treat since effective therapies are limited. This mediocre outcome can be partially explained by the presence of leukemia stem cells (LSC) that maintain an aberrant hematopoietic process. LSC in AML were traditionally thought to be solely CD34+CD38- cells. However, recent studies demonstrated the presence of LSC in cell fractions thought to be non-tumorigenic. Finding an LSC-specific signature would be decisive for a better categorization of patients and LSC exclusive targeting.
This project considers the signature of transposable elements (TEs) as an ideal tool for the identification of LSC. TEs, with important roles in gene regulation, are linked to the reprogramming process to pluripotency and they are associated with tumorigenesis. Since they contribute up to two thirds of the human genome, TEs expression provides much denser coverage of chromosomes than gene-derived transcriptome. TEs signature in cancer has so far been largely unexplored per lack of proper technologies. The advent of high-throughput sequencing and the development of TE-directed analytical pipelines allow now the accomplishment of this project.
The present proposal includes a comprehensive characterization of TEs transcriptome in normal and malignant hematopoietic precursors. An expected result is the achievement of a better subclassification of AML samples on the basis of their TEs expression homology to normal progenitors. The project will investigate the existence of TE-derived oncoproteins exclusive for LSC that could be immunotherapeutically targeted.
This proposal has impact on the excellence of European science since it will create new collaborations and networks to find AML biomarkers. It would bridge academy with industry and will bring invaluable complementary scientific and soft skills to a researcher with an ideal background in cancer epigenetics.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › allergology › drug allergy
• medical and health sciences › medical biotechnology › cells technologies › stem cells
• medical and health sciences › clinical medicine › oncology › colorectal cancer
• medical and health sciences › clinical medicine › oncology › leukemia
• natural sciences › biological sciences › genetics › epigenetics

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2016 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2016

Finanzierungsplan

MSCA-IF-EF-ST - Standard EF

Koordinator

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

• Netto-EU-Beitrag: € 175 419,60
• Adresse: BATIMENT CE 3316 STATION 1 ; 1015 Lausanne ; Schweiz
• Region: Schweiz/Suisse/Svizzera › Région lémanique › Vaud
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 175 419,60